Contract Extension with Johnson & Johnson

AI SummaryClose X

Trellus Health plc has secured a six-month contract extension with Johnson & Johnson Health Care Systems for its Trellus Elevate platform, supporting patients with inflammatory bowel disease, with the same economic terms including a fixed monthly management fee. This extension, effective until mid-2026, was driven by strong engagement and satisfaction metrics achieved during the initial pilot phase, leading J&J to broaden patient access channels. The company also continues to deploy its TrialSet™ solution with ICON plc for a Takeda-sponsored trial and with PSI Inc. for Sanofi-sponsored trials. For the year ended 2025, Trellus Health expects revenue of approximately $545,000 and has reduced its monthly cash burn to around $400,000. A £5 million convertible facility, approved by shareholders, is expected to extend the cash runway into late Q1 2026, with ongoing discussions for further funding.

Disclaimer*

UK 100

Latest directors dealings